Assessment of transporter-mediated drug–drug interaction (DDI) is integral to drug development. A risk-based approach leveraging in vitro, in vivo, and in silico information is used to evaluate the DDI liability of drugs and inform the instructions of use. While tremendous advances have been made in recent decades, there are knowledge gaps warranting further research. Herein, we focus on select areas to advance assessment of DDI potential for drugs as substrates, inhibitors, or inducers of certain transporters.

中文翻译：

---

当前对转运蛋白介导的药物相互作用评估中残留知识差距的看法

评估转运蛋白介导的药物-药物相互作用 (DDI) 是药物开发的组成部分。利用体外、体内和计算机信息的基于风险的方法用于评估药物的 DDI 责任并告知使用说明。尽管近几十年来取得了巨大的进步，但仍存在需要进一步研究的知识差距。在此，我们专注于选定领域，以推进对药物作为某些转运蛋白的底物、抑制剂或诱导剂的 DDI 潜力的评估。